Meeting
2022 ASCO Annual Meeting
Recombinant human endostatin combined with intensity-modulated radiotherapy in low-risk locoregionally advanced nasopharyngeal carcinoma: A phase II, randomized, multicenter clinical trial.
Authors
Min Kang
Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
Min Kang , Shaomin Lin , Haisheng Zhu , Sihui Liao , Haixin Huang , Bin Yu , Hongqian Wang , Meilian Liu , Jinxian Zhu , Guang Huang , Fen Wang , Tingting Zhang , Zhendong Yang , Pingting Zhou , Ziyan Zhou , Yating Qin , Yutao Qin , Zhuxin Wei , Changhong Zhao , Rensheng Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02237924
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6061)
DOI
10.1200/JCO.2022.40.16_suppl.6061
Abstract #
6061
Poster Bd #
53
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Endostar combined with intensity-modulated radiotherapy in low-risk local advanced nasopharyngeal carcinoma: A phase II, randomized, multicentric clinical trial.
First Author: Min Kang
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of diffusion-weighted MR imaging-guided radiotherapy plus chemotherapy versus standard chemoradiotherapy in locoregional advanced nasopharyngeal carcinoma.
First Author: Feng Liu
Poster
2018 ASCO Annual Meeting
Comparison between lobaplatin and cisplatin plus 5-fluorouracil combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized phase III clinical trial.
First Author: Kuiyuan Liu
Poster
2017 ASCO Annual Meeting
A phase II randomized, multicentric clinical trail comparing recombinant human endostatin plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locally advanced low-risk nasopharyngeal carcinoma.
First Author: Min Kang